Dana Dibenedetti1, Eileen Baranowski2, Susan Zelt3, Maria Reynolds1, Beth Sherrill1. 1. RTI Health Solutions, Research Triangle Park, North Carolina; 2. Stiefel, A GSK Company, Research Triangle Park, North Carolina ; Currently retired; 3. Stiefel, A GSK Company, Research Triangle Park, North Carolina ; Current affiliation: ViiV Healthcare, Research Triangle Park, North Carolina.
Abstract
OBJECTIVE: Patients with severe chronic hand eczema often have persistent symptoms that interfere with daily activities, social functioning, and employment. Many patients are refractory to topical corticosteroids. This survey-based study was performed to characterize treatment experiences, impact on productivity, and quality of life of patients with severe chronic hand eczema; understand dermatologists' severe chronic hand eczema treatment patterns. DESIGN: A web-based survey in the United States queried pre-identified patients with severe chronic hand eczema regarding symptoms, treatment history, quality of life, work productivity, treatment satisfaction, and healthcare utilization. In a separate survey, dermatologists were asked about treatment patterns and satisfaction with currently available therapies. RESULTS: The most commonly reported symptoms currently experienced by patients (n=163) were dryness/flaking (81%), itchiness (75%), and cracking/tearing of the skin (71%). Over the last three months, 84 percent of patients with severe chronic hand eczema self-reported using topical steroids, and 30 percent used systemic corticosteroids or retinoids. Approximately 30 percent reported impairment while working and productivity loss. Patient quality of life was negatively impacted. Dermatologists (n=125) reported most often treating severe chronic hand eczema with topical corticosteroids (99%), followed by topical immunomodulators (71%) and systemic treatments (70%). Only two percent were very satisfied with currently available products. CONCLUSION: Patients with severe chronic hand eczema experience symptoms that negatively impact work productivity and quality of life. Few dermatologists are very satisfied with currently available severe chronic hand eczema treatment options.
OBJECTIVE:Patients with severe chronic hand eczema often have persistent symptoms that interfere with daily activities, social functioning, and employment. Many patients are refractory to topical corticosteroids. This survey-based study was performed to characterize treatment experiences, impact on productivity, and quality of life of patients with severe chronic hand eczema; understand dermatologists' severe chronic hand eczema treatment patterns. DESIGN: A web-based survey in the United States queried pre-identified patients with severe chronic hand eczema regarding symptoms, treatment history, quality of life, work productivity, treatment satisfaction, and healthcare utilization. In a separate survey, dermatologists were asked about treatment patterns and satisfaction with currently available therapies. RESULTS: The most commonly reported symptoms currently experienced by patients (n=163) were dryness/flaking (81%), itchiness (75%), and cracking/tearing of the skin (71%). Over the last three months, 84 percent of patients with severe chronic hand eczema self-reported using topical steroids, and 30 percent used systemic corticosteroids or retinoids. Approximately 30 percent reported impairment while working and productivity loss. Patient quality of life was negatively impacted. Dermatologists (n=125) reported most often treating severe chronic hand eczema with topical corticosteroids (99%), followed by topical immunomodulators (71%) and systemic treatments (70%). Only two percent were very satisfied with currently available products. CONCLUSION:Patients with severe chronic hand eczema experience symptoms that negatively impact work productivity and quality of life. Few dermatologists are very satisfied with currently available severe chronic hand eczema treatment options.
Authors: Thomas L Diepgen; Peter Elsner; Sibylle Schliemann; Manigé Fartasch; Arno Köllner; Christoph Skudlik; Swen M John; Margitta Worm Journal: J Dtsch Dermatol Ges Date: 2009-05 Impact factor: 5.584
Authors: J Ring; A Alomar; T Bieber; M Deleuran; A Fink-Wagner; C Gelmetti; U Gieler; J Lipozencic; T Luger; A P Oranje; T Schäfer; T Schwennesen; S Seidenari; D Simon; S Ständer; G Stingl; S Szalai; J C Szepietowski; A Taïeb; T Werfel; A Wollenberg; U Darsow Journal: J Eur Acad Dermatol Venereol Date: 2012-07-19 Impact factor: 6.166
Authors: Linda Ruppert; Christian Apfelbacher; Sonja Molin; Andrea Bauer; Vera Mahler; Jochen Schmitt; Peter Elsner; Thomas L Diepgen; Elke Weisshaar Journal: Dermatology Date: 2014-08-16 Impact factor: 5.366
Authors: Thomas L Diepgen; Tove Agner; Werner Aberer; John Berth-Jones; Frédéric Cambazard; Peter Elsner; John McFadden; Pieter Jan Coenraads Journal: Contact Dermatitis Date: 2007-10 Impact factor: 6.600
Authors: Sau Huu Nguyen; Long Hoang Nguyen; Giang Thu Vu; Cuong Tat Nguyen; Thu Hoai Thi Le; Bach Xuan Tran; Carl A Latkin; Cyrus S H Ho; Roger C M Ho Journal: Int J Environ Res Public Health Date: 2019-01-23 Impact factor: 3.390
Authors: April Armstrong; Julie Hahn-Pedersen; Chris Bartlett; Julie Glanville; Jacob P Thyssen Journal: Am J Clin Dermatol Date: 2022-03-08 Impact factor: 6.233
Authors: Laura Grant; Lotte Seiding Larsen; Kate Burrows; Donald V Belsito; Elke Weisshaar; Thomas Diepgen; Julie Hahn-Pedersen; Ole E Sørensen; Rob Arbuckle Journal: Adv Ther Date: 2020-01-19 Impact factor: 3.845